Investing.com - Halozyme (NASDAQ: HALO) reported first quarter EPS of $0.79, $0.10 better than the analyst estimate of $0.69. Revenue for the quarter came in at $196M versus the consensus estimate of $199.74M.
Guidance
Halozyme sees FY 2024 EPS of $3.55-$3.90
Halozyme sees FY 2024 revenue of $915.00M-$985.00M
Halozyme's stock price closed at $41.21. It is up 16.12% in the last 3 months and up 36.10% in the last 12 months.
Halozyme saw 0 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Halozyme's stock price’s past reactions to earnings here.
According to InvestingPro, Halozyme's Financial Health score is "great performance".
Check out Halozyme's recent earnings performance, and Halozyme's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar